Topical effectiveness of different concentrations of nanosilver solution on Leishmania major lesions in Balb/c mice by Mohammad Ali Nilforoushzadeh , Leila Shirani-Bidabadi  , Azadeh Zolfaghari-Baghbaderani , Reza Jafari , Motahar Heidari-Beni , Amir Hossein Siadat  & Mehdi Ghahraman-Tabrizi
J Vector Borne Dis 49, Dec 2012, pp. 249–253
Topical effectiveness of different concentrations of nanosilver solution on
Leishmania major lesions in Balb/c mice
Mohammad Ali Nilforoushzadeh
1, Leila Shirani-Bidabadi
2, Azadeh Zolfaghari-Baghbaderani
2,
Reza Jafari
3, Motahar Heidari-Beni
4, Amir Hossein Siadat
2 & Mehdi Ghahraman-Tabrizi
2
1Skin & Stem Cell Research Center, Tehran University of Medical Sciences, Tehran; 2Skin Diseases & Leishmaniasis Research Center,
Isfahan University of Medical Sciences, Isfahan; 3National Institute of Health Research, Isfahan Health Research Station, Tehran University
of Medical Sciences, Tehran; 4Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
ABSTRACT
Background & objectives: Cutaneous leishmaniasis is an infection caused by protozoan genus Leishmania. Although
glucantime is commonly used for the treatment of leishmaniasis, it has some side effects including increased liver
enzymes and electrocardiogram changes. In addition, the drug is expensive, the injection is painful, and research
shows that resistance of parasite to glucantime is growing in different parts of the world. Therefore, scientists are
paying more attention to develop new drugs such as nanosilver solution. The present study is an attempt to
evaluate the in vivo topical effects of different concentrations of nanosilver solution in the treatment of leishmaniasis
lesions.
Methods: In all, 90 female Balb/c mice aged 6–8 wk were infected with 2×106 viable stationary-phase promastigotes
in the base of tail. Different concentrations (60, 80, 120, 130 and 2000 ppm) nanosilver solution were used in the
present study to test the efficacy in the treatment of lesions. Clinical control of the infection trends was conducted
weekly for 5 wk by measuring lesion diameter with standard Kulis-Vernieh. Data were analyzed by paired t-test,
analysis of variance (ANOVA), and Tukey test.
Results: Mean lesion diameter pre- and post-treatment did not significantly differ between different treatment
groups (p >0.05). Likewise, a significant difference in splenic parasite load was also not observed between different
treatment groups.
Interpretation & conclusion: Based on our results, different concentrations of nanosilver are ineffective in reducing
mean sizes of lesions.
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INTRODUCTION
Cutaneous leishmaniasis is an infection caused by
Leishmania parasites. According to findings ~15,000
people are affected annually in Iran. The real rate of inci-
dence is 4 to 5 times higher than the reported prev-
alence1, 2. Current therapies for treatment of Leishmania
are compounds of pentavalent antimony (pentostam and
glucantime) and amphotericin B, metronidazole,
diamydin, pentamidine, allopurinol, ketoconazole,
astrokonazol, dapson, monomycin, paramomycin, etc3–6.
These drugs have side effects; for example glucantime
elevate liver enzymes, change electrocardiogram, erupt
cutaneous, painful injection, resistance of parasites to
glucantime, etc.3, 4, 7. Disadvantage of glucantime and
other drugs have more side effects that caused research-
ers attempt to find new drugs with more efficacy and less
side effects.
Nanosilver solution is a new drug with anti-bacte-
rial, antifungal and antiviral properties. Advantages of
this drug compared to other drugs are efficacy at low con-
centration and long life duration8–10. Studies showed that
nanosilver cement has high antibacterial activity and high
effectiveness against multi resistant bacteria without
cytotoxicity in vitro11. Recently, findings have demon-
strated that nanosilver has anti-inflammatory effects and
increases wound healing and dressings of wounds12. If
these results are confirmed in vivo, nanosilver may be
appropriate for ulcer treatment. In this study, we evalu-
ated the effect of topical application of different concen-
trations of nanosilver solution on the leishmaniasis ulcer
in Balb/c mice.
MATERIAL & METHODS
Preparation of nanosilver solution
Nanosilver powder was used with average particle
size of 100 nm. We used colloid nanosilver particles (4000
ppm) that were manufactured by Nanoalvand Co., Iran.
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4000 were prepared in double deionized water immedi-
ately before use.
Parasite culture
Iranian Leishmania strains (MRHO/IR/75/ER) were
cultured in RPMI-1640 medium supplemented with
10% inactivated fetal calf serum (FCS), 100 mg/ml strep-
tomycin and 100 IU/ml penicillin G at 25°C13. The
promastigotes from stationary-growth phase of culture
were used to infect inbred Balb/c mice.
In vivo study
Female Balb/c mice, 6 to 8 wk old with approximately
60–80 g were procured from the Animal Breeding Stock
Facility of Pasteur Institute of Tehran. Exactly, 0.1 ml of
the solution containing 2×106 L. major promastigotes
(MRHO/IR/75/ER) was injected into the base of mice
tail subcutaneously. After injection, the mice were kept
in shelves in specific and appropriate conditions. After
5 wk, wound was formed at the base of the tail. The para-
sites were confirmed under a microscope after sampling
the wound and colored it.
Testing and treatment groups
After 5 wk of inoculation, when lesions appeared at
the base of tail, treatment was initiated. Animals were
divided into 9 groups with at least 10 animals in each
group. Clinical control of the infection trends was con-
ducted weekly for 5 wk by measuring lesion diameter
with standard Kulis-Vernieh. The animals were treated
as follows:
(1) Control group 1: Without inoculation of parasites;
(2) Control group 2: Parasites were injected without any
treatment; (3) Control group 3: Treated with only dis-
tilled water; (4) Control group 4: Positive control group
treated with peritoneal injection of amphotericin B
(6 mg/kg body weight) daily for two weeks; and (5) Treat-
ment group 1: Treated with intralesional injection of
nanosilver 60 ppm solution; (6) Treatment group 2:
Treated with intralesional injection of nanosilver 80 ppm
solution; (7) Treatment group 3: Treated with topical spray
of the nanosilver 120 ppm; (8) Treatment group 4: Treated
with topical spray of the nanosilver 130 ppm; and (9)
Treatment group 5: Treated with topical spray of the
nanosilver 2000 ppm.
In treatment groups, mice with one nodule were se-
lected. Nanosilver solutions was used in different con-
centrations (60, 80,120, 130 and 2000 ppm) and injected
five times intralesionally every 4th day up to 16 days.
Mice were followed for 5 wk and efficacy of nanosilver
solutions was investigated in groups. Light microscopy
was used with high magnification (×1000) for obser-
vation of amastigote forms in the smears prepared from
lesions.
Determination of spleen parasite load
Positive effect of nanosilver solution on parasite load
was investigated based on the method of cultivation (Limi-
ting dilution method) and buffer changing. Spleen para-
site load was determined in the second week after wound
appearance and 2 months post-treatment. The final con-
centration was diluted with the same medium. Total
weight of isolated organ (in this case is the spleen) was
determined. Approximately, 20 mg of tissue in between
two sterile glass slides in 1 ml medium (Graces insect
medium containing 15% bovine serum inactivated by
heat), was homogenized and the final concentration was
diluted with the same medium. Various dilutions were
prepared in the 96 well planted plates and were main-
tained for 3 week at 26°C. Wells were tested for 3 con-
secutive days for investigation of live promastigotes.
Maximum dilution that positive parasite had been dem-
onstrated was reported as concentration of parasite in
milligram. Spleen parasite load was determined in the
second week after wound appearance and 2 months post-
treatment14.
Statistical analysis
Statistical significance between groups was analyzed
by Paired t-test and two-way analysis of variance
(ANOVA) using SPSS version 17.5. Values of p <0.05
were considered statistically significant.
RESULTS
In vivo studies (Nanosilver effect on lesion size)
In all, five nanosilver treated groups were compared
with control groups, the mean lesion sizes did not de-
crease significantly after 5 wk treatment (p >0.05)
(Table 1). Statistically significant differences were not
found between treatment groups and control groups
pre- and 5 wk post-treatment (Table 2). In addition,
significant differences were not observed in spleen
parasite load pre- and post-treatment (p >0.05) (Fig. 1).
DISCUSSION
We didn’t find any significant difference in the ulcer
size, mean lesion diameter and spleen parasite load after
5 wk treatment with nanosilver solution. These findings
demonstrated that nanosilver treatment when compared
with control group reduced mastigote numbers and pro- 251 Nilforoushzadeh et al: Nanosilver solution on leishmaniasis lesions
Table 1. Therapeutic effects of different concentrations of nanosilver solution on the lesion sizes (mm) of cutaneous leishmaniasis induced by
L. major in Balb/c mice compared to control groups
Groups Time of treatment
Start Week 1 Week 2 Week 3 Week 4 Week 5 P-value*
(Mean ± SD) (Mean ± SD) (Mean ± SD) (Mean ± SD) (Mean ± SD) (Mean ± SD)
Control 6.87 ± 2.84 7.71 ± 2.31 9.38 ± 3.89 9.01 ± 2.13 10.46 ± 1.50 12.72 ± 2.73 0.108
Distilled water 5.47 ± 1.63 9.61 ± 2.27 10.36 ± 2.94 12.95 ± 2.68 12.67 ± 0.035 13.15 ± 1.97 0.307
Amphotericin 4.91 ± 0.601 6.08 ± 2.49 8.48 ± 2.96 7.58 ± 1.48 6.85 ± 1.12 6.75 ± 0.74 0.131
B (+) control
Topical inj. 60 ppm 7.44 ± 2.74 10.41 ± 3.41 10.21 ± 1.54 10.63 ± 3.56 10.08 ± 2.92 13.26 ± 1.31 0.127
Topical inj. 80 ppm 7.20 ± 2.64 8.03 ± 1.14 10.56 ± 2.82 9.69 ± 4.21 9.91 ± 2.51 10.81 ± 2.44 0.448
Topical spray 120 ppm 7.24 ± 1.88 10.41 ± 3.87 12.9 ± 5.08 14.3 ± 9.01 11.30 ± 2.17 9.20 ± 3.53 0.281
Topical spray 130 ppm 7.40 ± 1.91 10.30 ± 2.11 10.17 ± 2.20 9.70 ± 3.34 12.16 ± 5.42 12.52 ± 7.03 0.677
Topical spray 2000 ppm 6.54 ± 1.44 9.29 ± 1.81 10.96 ± 1.25 11.66 ± 2.46 15.05 ± 3.46 13.66 ± 2.86 0.534
*Statistical test ANOVA.
Fig. 1: Comparison of splenic parasite load in pre- and post-treatment
of mice for the different groups.
infection was significantly decreased in nanosilver-treated
groups compared with control groups. According to a
previous study, spleen parasite load decreased signifi-
cantly after treatment with nanosilver solution15. One ran-
domized clinical trial demonstrated that wound healing
time in nanosilver treated groups compared with control
groups decreased significantly and nanosilver increased
bacterial clearance from infected wounds. Nanosilver use
did not have any adverse effect for healing16. Another
study showed that nanosilver decreased the wound heal-
ing time in superficial burn wounds but not deep burn
wounds and demonstrated that it enhances re-epitheliza-
tion and don’t have any effect on other phase of wound
healing such as new tissue formation, angiogenesis and
proliferation17.
Silver has been used to treat different infections
for many years; silver nano-particle form usage has
liferation of them but this reduction was not significant.
In addition, different concentrations of nanosilver didn’t
decrease the mean lesion size significantly. Secondary
Table 2. Comparison of lesion size of cutaneous leishmaniasis in Balb/c mice treated with different concentrations of
nanosilver solution in pre- and post-treatment
Groups Size of lesion (mm) P-value
Pre-treatment Post-treatment
Mean ± S.D. Mean ± S.D.
Control group (n=5) 6.87 ± 2.84 12.72 ± 2.73 0.108
Distilled water (n=5) 5.47 ± 1.63 13.15 ± 1.97 0.307
Amphotericin B (n=5) 4.91 ± 0.601 6.75 ± 0.74 0.131
Topical inj. 60 ppm  (n=5) 7.44 ± 2.74 13.26 ± 1.31 0.127
Topical inj. 80 ppm  (n=5) 7.20 ± 2.64 10.81 ± 2.44 0.448
Topical spray120 ppm  (n=5) 7.24 ± 1.88 9.20 ± 3.53 0.281
Topical spray130 ppm (n=5) 7.40 ± 1.91 12.52 ± 7.03 0.677
Topical spray 2000 ppm (n=5) 6.54 ± 1.44 13.66 ± 2.86 0.534 J Vector Borne Dis 49, December 2012 252
opened new ways of treatment with development of
nano-technology14. Nanosilver compounds show impact
on a wide range of microorganisms including bacteria,
viruses, fungi, and even protect against protozoa and in-
fluenza15, 18, 19 .
Recent studies suggested that nanosilver has a potent
anti-inflammatory effect and enhance wound healing.
Nanosilver has antibacterial effects against a large num-
ber of bacterial species. According to findings, bacterial
resistance to elemental silver is extremely rare12. The ex-
act mechanisms of antibacterial effect of nanosilver are
not yet elucidated. Some possible mechanisms are effec-
tive on peptidoglycan cell wall, the plasma membrane,
bacterial (cytoplasmic) DNA, bacterial proteins especially
enzymes involved in vital cellular processes12. Accord-
ing to some findings, antibacterial effect of nanosilver is
size and dose dependent. Smaller sizes of nanosilver have
more antibacterial effects and exhibit more on various
range of bacteria20,21.
 Few findings showed that nanosilver is more effec-
tive on gram-negative bacteria than gram-positive bacte-
ria. Gram-negative bacteria are more sensitive to nano-
silver than gram-positive bacteria22, 23.
 Despite the beneficial effects of nanosilver, toxicity
of nanosilver is still unknown. Nanosilver damage DNA,
denature proteins and enzymes and produce free radicals
and some studies showed that nanosilver is cytotoxic to
several different cell lines. The teratogenicity of nanosilver
in humans is indistinctive and is not reported in the litera-
ture but in vivo (animal studies) and in vitro studies showed
nanosilver can exhibit a significant level of toxicity. So
prescription of nanosilver for healing wounds in human
needs to be investigated24, 25.
CONCLUSION
Based on our results, different concentrations of
nanosilver are ineffective in reducing mean sizes of le-
sions. However, nanosilver can be used in treating sec-
ondary infections of cutaneous leishmaniasis.
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